Cargando…

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

While antibody engineering improves the properties of therapeutic antibodies, optimization of regions that do not contact antigens has been mainly focused on modifying the effector functions and pharmacokinetics of antibodies. We recently reported an asymmetric anti-FIXa/FX bispecific IgG(4) antibod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampei, Zenjiro, Igawa, Tomoyuki, Soeda, Tetsuhiro, Funaki, Miho, Yoshihashi, Kazutaka, Kitazawa, Takehisa, Muto, Atsushi, Kojima, Tetsuo, Nakamura, Satoshi, Hattori, Kunihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622617/ https://www.ncbi.nlm.nih.gov/pubmed/25524207 http://dx.doi.org/10.4161/19420862.2015.989028

Ejemplares similares

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
por: Sampei, Zenjiro, et al.
Publicado: (2013)

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017)

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro
por: Noguchi-Sasaki, Mariko, et al.
Publicado: (2018)

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential
por: Nakajima, Yuto, et al.
Publicado: (2022)

Efficient production of bispecific antibody by FAST-Ig(TM) and its application to NXT007 for the treatment of hemophilia A
por: Koga, Hikaru, et al.
Publicado: (2023)

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
por: Sampei, Zenjiro, et al.
Publicado: (2018)

A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa
por: Kundu, Sibsankar, et al.
Publicado: (2021)

Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
por: Ankrom, Wendy, et al.
Publicado: (2016)

Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa
por: Yoon, Hyun Jung, et al.
Publicado: (2023)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Regulation of collective cell migration by RhoGAP myosin IXA
por: Omelchenko, Tatiana
Publicado: (2012)

Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO
por: Reed, Christopher R., et al.
Publicado: (2021)

Development of selective bispecific Wnt mimetics for bone loss and repair
por: Fowler, Tristan W., et al.
Publicado: (2021)

Myosin IXa Binds AMPAR and Regulates Synaptic Structure, LTP, and Cognitive Function
por: Folci, Alessandra, et al.
Publicado: (2016)

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays
por: Adamkewicz, Joanne I., et al.
Publicado: (2019)

Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults
por: Persson, Paula, et al.
Publicado: (2023)

Circulating Contact-Pathway-Activating Microparticles Together with Factors IXa and XIa Induce Spontaneous Clotting in Plasma of Hematology and Cardiologic Patients
por: Lipets, Elena, et al.
Publicado: (2014)

SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa
por: Childers, Kenneth C., et al.
Publicado: (2022)

The Interaction of Factor Xa and IXa with Non-Activated Antithrombin in Michaelis Complex: Insights from Enhanced-Sampling Molecular Dynamics Simulations
por: Balogh, Gábor, et al.
Publicado: (2023)

A new variant in PHKA2 is associated with glycogen storage disease type IXa
por: Rodríguez-Jiménez, Carmen, et al.
Publicado: (2017)

Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering
por: Hori, Yuji, et al.
Publicado: (2022)

Soluble Phosphatidylserine Binds to Two Sites on Human Factor IXa in a Ca(2+) Dependent Fashion to Specifically Regulate Structure and Activity
por: Majumder, Rinku, et al.
Publicado: (2014)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells
por: Sakurai, Yoshihiko, et al.
Publicado: (2013)

Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives
por: Gao, Jia-Suo, et al.
Publicado: (2015)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)

Platelet Function and Factor VIII in Uremia(*)
por: Park, Hee Sook, et al.
Publicado: (1987)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII
por: Grushin, K, et al.
Publicado: (2014)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
por: Fukuzawa, Taku, et al.
Publicado: (2017)

Subcellular platelet factor VIII antigen and von Willebrand factor
Publicado: (1975)

Acquired Factor VIII Inhibitors: Three Cases
por: Kyaw, Tay Za, et al.
Publicado: (2013)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
por: Scott, David W., et al.
Publicado: (2020)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Mutation in PHKA2 leading to childhood glycogen storage disease type IXa: A case report and literature review
por: Zhu, Qian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gf7aipchsdfk6aqcanqtn01eqi